Health Care/Hospital

International Self-Care Day: Dimora Medical Highlights Wound Care as an Essential Part of Everyday Self-Care

NEW YORK, July 24, 2026 /PRNewswire/ -- As International Self-Care Day draws attention to the importance of maintaining health around the clock, the concept of 24/7 self-care continues to gain momentum among consumers seeking more proactive approaches to everyday well-being. While nutrition, exer...

2026-07-25 01:50 1792

Nova Biomedical Advances Integrated Cell Line Development Workflows: NanoCellect products are now part of Nova Biomedical

WALTHAM, Mass., July 24, 2026 /PRNewswire/ -- Nova Biomedical today announced a transaction involving certain assets of NanoCellect, a provider of microfluidic cell sorting technology. This expands Nova Biomedical's capabilities in cell line development and strengthens its ability to support bio...

2026-07-24 22:05 1814

Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients

PALMA DE MALLORCA, Spain, July 24, 2026 /PRNewswire/ -- Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid therapy approach, today announced that the last patient has completed their last visit (LPLV) in the company's Phase 2b/3 clinical trial of i...

2026-07-24 09:30 1137

ArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406

SHANGHAI, July 24, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial with AK0406, a novel long-acting antiviral-Fc conjugate (AFC) drug for influenza prophylaxis. The clini...

2026-07-24 09:00 911

Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 23, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced a ...

2026-07-24 08:02 2393

Fapon Showcases AI-Engineered Enzymes and Alzheimer's Solutions at ADLM 2026, Reinforcing North American Commitment

ANAHEIM, Calif., July 23, 2026 /PRNewswire/ -- Fapon, a trusted global IVD provider with deepening roots in North America, will exhibit at ADLM 2026 from July 26 to 30 in Anaheim, California. The company will introduce novel AI-engineered enzymes for molecular diagnostics alongside a full suite o...

2026-07-24 01:10 1618

AH-008 Achieves Key Clinical Milestone with Successful First Subject First Dose (FSFD) in Phase I Study for Prevention of Chemotherapy-Induced Peripheral Neuropathy (CIPN)

TAIPEI, July 23, 2026 /PRNewswire/ -- AnHorn Medicines today announced the successful completion of the first subject first dose in the Phase I clinical trial of AH-008, a first-in-class neuroprotective candidate being developed to prevent chemotherapy-induced peripheral neuropathy (CIPN). This m...

2026-07-23 22:00 1638

Zhongchao Inc. Announces $5.0 Million Registered Direct Offering

SHANGHAI, July 23, 2026 /PRNewswire/ -- Zhongchao Inc ("Zhongchao" or the "Company") (NASDAQ: ZCMD), today announced that it has entered into a definitive agreement with certain investors for the purchase and sale of an aggregate of4,545,455 of the Company's Class A Ordinary Shares, par value $0...

2026-07-23 21:00 1666

NYSE Content Update: Fourth Annual AI x Bio Summit to Commence at the NYSE

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, July 23, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begin...

2026-07-23 20:55 1726

PUBLIC TRUST IN HEALTH INNOVATION IS SHAPED MORE BY MINDSET THAN DEMOGRAPHICS, DNV RESEARCH FINDS

OSLO, Norway, July 23, 2026 /PRNewswire/ -- Public trust in health innovation may be less predictable than healthcare organizations assume, according to new research from DNV, the independent assurance and certification provider.

2026-07-23 20:34 893

Samsung Galaxy Watch Ultra2 and Watch9: Life Companion on Your Wrist for Your Healthier Living

From Everyday Wellness to Effortless Health Management All-at-once with uncompromising performance and comfort SYDNEY, July 23, 2026 /PRNewswire/ -- Samsung Electronics Co., Ltd has announced the all-newGalaxy Watch Ultra2 and Galaxy Watch9,[1] delivering a new era of effortless health, where us...

2026-07-23 17:16 1460

AXA Survey Reveals Menopause Awareness Gap Among Hong Kong Working Women

Misconceptions deny women a critical ten-year window for health management, highlighting urgent need for greater awareness and stronger employer care HONG KONG, July 23, 2026 /PRNewswire/ -- Findings from the AXA Hong Kong Female Health Survey 2026[1] ("the Study") conducted by AXA Hong Kong and...

2026-07-23 16:28 798

Haisco's Class 1 Innovative Drug Ciprocopan Succinate Tablets Approved in China, Offering a New Treatment Option for Patients With PNH

BEIJING, July 23, 2026 /PRNewswire/ -- Haisco Pharmaceutical Group claimed today their independently developed Class 1 innovative drug, Ciprocopan Succinate Tablets (development code: HSK39297), has receivedmarketing approval from the National Medical Products Administration of China (NMPA) for t...

2026-07-23 14:08 626

GHIT Fund Invests Approx. JPY 140 Million in a Portable Rapid Diagnostic System for Ebola Disease in a Joint Project Between Osaka Metropolitan University, K.K. DNAFORM, and INRB

TOKYO, July 23, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today an investment of JPY 140 million (approximately USD 862,000) in a project to develop a portable rapid diagnostic system for Ebola disease. The system is being jointly developed by Osaka Metrop...

2026-07-23 12:01 1156

The longer we live, the more we worry: AIA Longevity Study finds Singaporeans view longevity with more anxiety than opportunity

New findings reveal that Singaporeans' concerns about living longer stem from a growing awareness–action gap: Despite understanding what it takes to age well, many are unprepared, with significant gaps in their financial preparedness, healthcare protection and long-term care planning. SINGAPORE,...

2026-07-23 11:00 1566

Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting

- Fixed-dose combination of ASC36 and ASC35 (ASC36_35 FDC) demonstrated superior weight loss compared to eloralintide in combination with tirzepatide in a diet-induced obese (DIO) animal model. HONG KONG, July 23, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that ...

2026-07-23 08:10 1865

Samsung Biologics Reports Second Quarter 2026 Financial Results

* Recorded Q2'26 revenue of KRW 1,321 billion and operating profit of KRW 586 billion * Delivered stable business performance through continued disciplined execution * Expanded global presence while advancing innovation and future growth initiatives INCHEON, South Korea, July 23, 2026 /PRNe...

2026-07-23 07:03 2138

HKEY-AI4AI-Atlas™ 1.0: HKeyBio Uses AI to Curate Autoimmune Model Datasets

HKEY-AI4AI-Atlas™ 1.0 uses AI-assisted dataset curation to support model selection, endpoint design and cross-species interpretation BOSTON and SUZHOU, China, July 22, 2026 /PRNewswire/ -- HKeyBio is building HKEY-AI4AI-Atlas™ 1.0, its AI-Assisted Autoimmune Model Data Atlas. The internal capabi...

2026-07-22 21:16 1954

Targeting the $100 Billion Market: Insilico Medicine Nominates AI-driven Novel PCC ISM9528 for Pain Management

* AI-Driven New Mechanism Discovery: Targeting an undisclosed novel mechanism empowered by PandaOmics, the PCC ISM9528 offers a potential first-in-class,brain -penetrant, non-opioid solution for pain management. * Superior Therapeutic Profile: In preclinical studies, ISM9528 demonstrated super...

2026-07-22 21:00 3118

Ribo Discloses Positive Data from Vortosiran Phase 2a Trial - World's First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease

SHANGHAI and MOLNDAL, Sweden, July 22, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd.  (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") today announce at China Pharmaceutical Innovation Conference (CPIC) in Shanghai, the positive results fro...

2026-07-22 20:28 3360
12345 ... 855